Ftse Mib
34.339,32
0,55%
DAX
18.686,60
1,07%
S&P 500
5.214,08
0,51%
NASDAQ
16.346,26
0,27%
Bitcoin
62.791,53
-0,41%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cyclerion Therapeutics Inc (CYCN) Cyclerion Therapeutics Inc (CYCN) Notizie

CYCN

Cyclerion Therapeutics (CYCN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CYCN
DataOraFonteTitoloSimboloCompagnia
07/05/202422:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYCNCyclerion Therapeutics Inc
26/01/202422:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYCNCyclerion Therapeutics Inc
11/12/202323:09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CYCNCyclerion Therapeutics Inc
07/12/202322:05Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:CYCNCyclerion Therapeutics Inc
04/12/202323:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYCNCyclerion Therapeutics Inc
04/12/202314:00GlobeNewswire Inc.Cyclerion Appoints Regina Graul, Ph.D., as PresidentNASDAQ:CYCNCyclerion Therapeutics Inc
01/12/202300:16GlobeNewswire Inc.Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge InnovatorNASDAQ:CYCNCyclerion Therapeutics Inc
31/07/202313:00GlobeNewswire Inc.Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion AssetsNASDAQ:CYCNCyclerion Therapeutics Inc
20/06/202322:56Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:CYCNCyclerion Therapeutics Inc
09/06/202323:24Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:CYCNCyclerion Therapeutics Inc
01/06/202322:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CYCNCyclerion Therapeutics Inc
01/06/202322:00GlobeNewswire Inc.Cyclerion Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:CYCNCyclerion Therapeutics Inc
23/05/202322:00Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:CYCNCyclerion Therapeutics Inc
15/05/202319:00GlobeNewswire Inc.Cyclerion Announces Reverse Stock SplitNASDAQ:CYCNCyclerion Therapeutics Inc
12/05/202312:05Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CYCNCyclerion Therapeutics Inc
12/05/202300:00GlobeNewswire Inc.Cyclerion Announces Definitive Agreement for Zagociguat and CY3018NASDAQ:CYCNCyclerion Therapeutics Inc
12/05/202300:00GlobeNewswire Inc.Cyclerion Announces Corporate Updates and Q1 2023 Financial ResultsNASDAQ:CYCNCyclerion Therapeutics Inc
03/04/202313:30GlobeNewswire Inc.Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment AgreementNASDAQ:CYCNCyclerion Therapeutics Inc
27/03/202313:00GlobeNewswire Inc.Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial DiseasesNASDAQ:CYCNCyclerion Therapeutics Inc
22/03/202322:01Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:CYCNCyclerion Therapeutics Inc
22/03/202321:40GlobeNewswire Inc.Cyclerion Reports Corporate Update and Full Year 2022 Financial ResultsNASDAQ:CYCNCyclerion Therapeutics Inc
09/02/202316:02Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CYCNCyclerion Therapeutics Inc
13/01/202322:31Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CYCNCyclerion Therapeutics Inc
22/11/202213:00GlobeNewswire Inc.Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The CompanyNASDAQ:CYCNCyclerion Therapeutics Inc
21/10/202223:14Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:CYCNCyclerion Therapeutics Inc
06/10/202214:00GlobeNewswire Inc.Cyclerion Announces Mitochondrial Disease-Focused Corporate StrategyNASDAQ:CYCNCyclerion Therapeutics Inc
10/08/202222:46Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:CYCNCyclerion Therapeutics Inc
09/08/202222:00GlobeNewswire Inc.Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial ResultsNASDAQ:CYCNCyclerion Therapeutics Inc
28/07/202213:00GlobeNewswire Inc.Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)NASDAQ:CYCNCyclerion Therapeutics Inc
26/07/202222:34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CYCNCyclerion Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CYCN

La tua Cronologia

BIT
BPE
Bper Banca
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
NEXI
Nexi S.p.A
BIT
BAMI
Banco BPM
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
PRY
Prysmian
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
FBK
Finecobank
BIT
TIT
Telecom Italia
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network